Under the terms of the agreement, the two companies will work jointly to develop an application of OmniSonics’s OmniWave technology for the treatment of acute ischemic stroke. The OmniWave technology, which delivers low-power ultrasonic energy to remove thrombus, was recently launched in the US for the treatment of clots in the peripheral vasculature.
Boston Scientific will provide funding based on the achievement of development milestones and has an option to acquire the technology as well as exclusive rights to the intellectual property for the treatment of acute stroke.
Richard Ganz, president and CEO of OmniSonics, said: “OmniSonics is excited to enter into this agreement with Boston Scientific. We are hopeful our OmniWave technology will prove to be an effective option for patients suffering from acute stroke.”